key: cord-1038138-l6t0jice
authors: Rosenfeld, Ronit; Noy-Porat, Tal; Mechaly, Adva; Makdasi, Efi; Levy, Yinon; Alcalay, Ron; Falach, Reut; Aftalion, Moshe; Epstein, Eyal; Gur, David; Chitlaru, Theodor; Vitner, Einat B.; Melamed, Sharon; Politi, Boaz; Zauberman, Ayelet; Lazar, Shirley; Evgy, Yentl; Yitzhaki, Shmuel; Shapira, Shmuel C.; Israely, Tomer; Mazor, Ohad
title: Post-exposure protection of SARS-CoV-2 lethal infected K18-hACE2 transgenic mice by neutralizing human monoclonal antibody
date: 2020-10-26
journal: bioRxiv
DOI: 10.1101/2020.10.26.354811
sha: 2ba9695e32a54ec7e7a78098d8db9c5ab8bb97c3
doc_id: 1038138
cord_uid: l6t0jice

Coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), exhibits high levels of mortality and morbidity and has dramatic consequences on human live, sociality and global economy. Neutralizing antibodies constitute a highly promising approach for treating and preventing infection by this novel pathogen. In the present study, we characterized and further evaluated the recently identified human monoclonal MD65 antibody for its ability to provide protection against a lethal SARS-CoV-2 infection of K18-hACE2 transgenic mice. 75% of the untreated mice succumbed 6-9 days post-infection while administration of the MD65 antibody as late as 3 days after exposure, rescued all infected animals. The data unprecedentedly demonstrate, the therapeutic value of human monoclonal antibodies as a life-saving treatment of severe COVID-19 infection.

Human monoclonal antibodies (mAbs), specifically targeting surface viral proteins, have increasingly demonstrated prophylactic and therapeutic efficacy against various viruses including HIV, Ebola, and the pathogenic beta-coronaviruses MERS-CoV and SARS-CoV [1] [2] [3] [4] [5] . Neutralizing antibodies constitute a highly promising approach for treating and preventing infection by the novel SARS-CoV-2 6 . The viral surface spike glycoprotein, is essential for viral attachment, fusion and entry into human cells and thus considered as the major target for therapeutic neutralizing antibodies [7] [8] [9] [10] [11] [12] [13] .

Specifically, highly potent neutralizing antibodies target and block the binding of the receptor binding domain (RBD) located in the S1 subunit of the spike, to the human angiotensin-converting enzyme 2 (hACE2) 7,10 ,14 .

A reliable animal model for COVID-19, is essential for the development of anti-SARS-CoV-2 countermeasures and for deciphering the pathogenicity of the disease 15 .

Accordingly, mouse models that exploit the recombinant hACE2 expression, either by transgenic or viral-transduction approaches were developed [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] . A transgenic mouse strain expressing hACE2 under the K18 promoter (K18-hACE2) was shown to be highly susceptible to SARS-CoV-2 infection, resulting in significant viral load in the lungs, heart, brain and spleen as well as mortality 26, 27 . In response to the urgent need for antibody-based therapy for COVID-19, several reports have demonstrated efficacy against SARS-CoV-2 infection by neutralizing antibodies, primarily as prophylactic protection 10, 19, [28] [29] [30] . These studies were based on non-lethal COVID-19 models of mice transduced to express hACE2, and did not demonstrate the efficacy of Ab-based passive therapy administered at a significant time post-infection.

We have previously reported the isolation of human neutralizing Abs selected against SARS-CoV-2 RBD by extensive screening of a phage-display library generated from lymphocytes collected from infected individuals. Among these Abs, MD65 exhibited the highest neutralization potency in vitro 11 . The aim of the current study was to evaluate the therapeutic efficacy of this Ab in a lethal COVID-19 animal model by assessing its prophylaxis and treatment abilities to protect K18-hACE2 infected mice.

Reformatting and characterization of the MD65 antibody. The initial binding and neutralization characterization of MD65 Ab were conducted following the expression of this antibody as a single-chain human-Fc recombinant form (scFv-Fc) 11 . Here, towards implementation of this antibody as a bona-fide therapeutic product appropriate for human use, it was re-cloned and produced as a full recombinant IgG molecule of the IgG1/k isotype which includes the triple mutation M252Y/S254T/T256E (YTE) in the Fc region. These modifications increase the antibody affinity towards the human FcRn 31 at acidic pH and thereby prolong its serum half-life, a parameter that is essential for a high therapeutic value [32] [33] [34] . Characterization of three versions of the MD65 Ab: scFv-Fc, IgG and IgG-YTE, established that overall they are highly comparable with regard to their antigen-binding performance (Fig. 1a) and that the IgG versions exhibit slightly favorable affinity when compared to the scFv-Fc one (apparent KD of 0.7 nM versus 1.0 nM, respectively). Similarly, the two MD65 IgG formats possess equivalent SARS CoV-2 neutralization potency in vitro (NT50 of 40 ng/ml) which is slightly better than that of the scFv-Fc antibody (NT50 of 67 ng/ml; Fig. 1b ). In addition, all three Ab versions were shown to effectively prevent the binding of SARS-CoV-2 spike RBD to the hACE2, again with favorable kinetics for the IgG formats (Fig. 1c) . These slight differences may indicate that there is a correlation between antibody affinity and SARS CoV-2 neutralization. This aspect will be further clarified in future studies. 

A pre-requisite for achieving long circulatory half-life of a given antibody in humans, is to improve its interaction with the FcRn at low pH. We therefore verified that MD65 in its IgG-YTE format, as anticipated, exhibits improved pharmacokinetic abilities compared to the WT IgG format.

Accordingly, the interactions of MD65 IgG and IgG-YTE with human FcRn, at pH 6.0 were assessed by biolayer interferometry (BLI). As expected, the modified antibody demonstrated a marked increase in affinity compared to the non-modified version, manifested by a three-fold improved on-rate and significant lower off-rate of binding ( Fig. 2a and b) . Steady-state analysis of these interactions revealed that the overall affinity of the IgG-YTE version toward human FcRn at low pH is 10-fold higher than the IgG version (Fig. 2c ).

As part of the pre-clinical evaluation of MD65 IgG-YTE antibody and prior to the examination of its therapeutic potency in K18-hACE2 mice, we determined the pharmacokinetic profile following intravenous (IV) or intraperitoneal (IP) administration. Accordingly, MD65 IgG-YTE was first intravenously injected to K18-hACE2 mice and plasma antibody levels at various time points were determined by ELISA. The data were fitted by non-linear regression, establishing that MD65 IgG-YTE exhibits a biphasic elimination profile (Fig. 2d) , consisting of a typical relatively short distribution phase () with a t1⁄2 value of about 180 min and a significantly longer elimination phase (β) with a t1⁄ 2 value of about 4,700 min (3.3 days; Fig. 2f ). These results are in good agreement with our previous observation that a chimeric protein bearing the same Fc (non YTE) exhibited similar pharmacokinetic parameters in mice 35 , corroborating the notion that these mutations do not affect the antibody interaction with the murine FcRn.

The plasma levels of MD65 IgG-YTE following IP administration was then evaluated.

The antibody exhibited a rapid and high bioavailability, reaching Cmax of 40 g/ml within 180 min, which is similar to its sera concentration at the same time point as observed following the IV-administration (Fig. 2e) . The elimination phase t1⁄2 value following IP administration was approximately 5300 min (3.7 days; Fig. 2f ). Therefore, the pharmacokinetic evaluation of the two alternative routes of administration indicate that they both are appropriate for the subsequent protection studies.

Kinetics of the interactions between human FcRn and MD65 variants (a IgG; b IgG-YTE) at pH 6.0, using BLI. Immobilized antibodies were interacted with the indicated concentrations of human FcRn for 60 sec (association phase) followed by a wash step (dissociation phase). c Steady-state analysis of sensorgrams by 1:1 binding model was used to determine equilibrium KD. d and e Plasma MD65 IgG-YTE concentrations in K18-hACE2 mice were determined at the indicated time points following a single (d) IV (n=4) or (e) IP (n=5) administration of 0.2 mg Ab. Values are expressed as mean ± SEM that were fitted using non-compartmental analysis. f Pharmacokinetic parameters of MD65 IgG-YTE.

To directly assess the use of the MD65 antibody as the basis for pre-and post-exposure therapy to countermeasure the SARS-CoV-2 infection, the K18-hACE2 transgenic murine model, was employed for in vivo neutralizing studies. This model was recently shown to fatefully recapitulate the SARS-CoV-2 infection and consequently to serve as a reliable model to predict the efficacy of therapeutic strategies 18,26 27,36 .

Infection of K18-hACE2 mice with 200 PFU of the SARS-CoV-2 BavPat1/2020 strain, resulted in massive weight loss from day 5 after infection and death of 75% of the animals at days 6 to 9 post infection ( Fig. 3b and 3c ).

In order to maintain a steady antibody levels in the circulation for about 8 days (the mean time to death in the control group), and taking into consideration the pharmacokinetic profile of the antibody, it was administered via the IP route in two successive treatments, 4 days apart. In sharp contrast to mock-treated mice (administered with PBS only), pre-exposure IP-administration of the MD65 antibody 4 h before infection (first dose) resulted in full protection of the infected animals without any signs of weight loss ( Fig. 3b and 3c ) or any other clinical symptoms. The high lethality of the infection could not be alleviated in mice administered with an isotype antibody control (MH75) that contains the same Fc but targets a non-relevant antigen (ricin) 37 .

The successful pre-exposure treatment of the infected mice prompted us to further evaluate the possibility to initiate treatment at even later time-points. K18-hACE2 mice were therefore infected with SARS-CoV-2 and IP-administered (first dose) with the MD65 antibody 1, 2, 3 or 4 days post-infection (dpi). It was found that treatment of infected mice initiated as late as 2 days after infection, was highly efficient in blocking the disease, as demonstrated by the complete prevention of weight loss and, most notably, by total protection of the mice (Fig. 3d and 3e) . Furthermore, even when treatment was initiated 3 dpi, all treated animals survived. Yet, mice in this experimental group displayed some mild symptoms during the first 10 dpi, as manifested by moderate delay in the gain of weight, compared to the non-infected naive animals. Further delaying the treatment to 4 dpi resulted in a protection rate of 60% of the infected animals without a significant delay in the time to death (for the nonsurviving animals). Taken together, these results demonstrate, for the first time, the therapeutic value of human monoclonal antibodies as a life-saving treatment of severe and lethal COVID-19 infection model. As several studies have shown that most SARS-CoV-2 neutralizing antibodies target the S1 subunit and even more specifically the RBD, the humoral responses of the antibody-treated mice toward these two antigens was further evaluated.

Indeed, a similar pattern was observed for these two antigens as for the spike (Fig. 4b and 4c), suggesting that the endogenous antibody response may contain SARS-CoV-2 neutralizing antibodies that will confer partial or full protection against re-infection.

Determination of the neutralization titer of these samples could provide further support for this concept, yet such an experiment is complicated by the masking effect of residual MD65 Ab. MD65 scFv, derived from a phage-display library, was initially cloned as a scFv-Fc Ab, as recently described 11 . To generate a full-length IgG, the VH and VL fragments where re-cloned into pcDNA3.1-Heavy and pcDNA3.1-Kappa vectors, respectively.

These vectors, were designed in to include IgG1 and Kappa chain constant domains, as well as the appropriate signal sequences for the production of complete heavy and light chains. The resulting antibody was further engineered to include three point mutations in its Fc region: M252Y/S254T/T256E (YTE mutations). These mutations were previously shown to increase antibody affinity to the human FcRn, at pH 6.0 and hence, to improve the Ab's serum half-life in rhesus macaques and humans 31, 33, 34 . The antibody MD29 scFc-Fc, reported to target RBD and neutralize SARS-CoV-2 but not inhibit ACE2-RBD interaction 11 , was similarly cloned and expressed as IgG-YTE.

Recombinant antibodies (scFv-Fc, IgG and IgG-YTE) were expressed using ExpiCHO TM Expression system (Thermoscientific, USA, Cat# A29133) and purified on HiTrap Protein-A column (GE healthcare, UK).

All purified proteins were sterile-filtered and stored in PBS. The integrity and purity of the recombinant expressed proteins were confirmed by SDS-PAGE analysis (Supplementary Figure 1) .

Direct ELISA was performed against SARS-CoV-2 S1 subunit (expressed and purified as recently described 11 ) for binding evaluation and for Ab concentration determination.

Maxisorp 96-well microtiter plates (Nunc, Roskilde, Denmark) were coated overnight with 1 μg/ml of S1 protein in NaHCO3 buffer (50 mM, pH 9.6), washed, and blocked with PBST at room temperature for 1 h. Human Abs were visualized by AP-conjugated containing exogenously-added known concentration of the Ab. Standard curve confirmed as above, were calculated for each individual ELISA plate/data set.

The endogenous humoral response was tested in mice sera samples collected at 14 dpi, evaluated by ELISA against SARS-CoV-2 spike, S1 and RBD essentially as described above, using AP-conjugated Donkey anti-mouse IgG (H+L) minimal cross (Jackson ImmunoResearch, USA, Cat# 715-055-150, lot 142717) used at 1:2,000.

Binding studies were carried out using the Octet system (ForteBio, USA, Version 8. ExpiCHO-S (Thermoscientific, USA, Cat# A29127) were used for expression of recombinant proteins as described above.

Handling of SARS-CoV-2 was conducted in a BSL3 facility in accordance with the 

Treatment of animals was in accordance with regulations outlined in the U.S. 

All data are available from the corresponding authors upon reasonable request.

Research; ohadm@iibr.gov.il) for research purposes only under an MTA, which allows the use of the antibody for non-commercial purposes but not its disclosure to third parties.

Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus

Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge

Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies

Human Neutralizing Monoclonal Antibody Inhibition of Middle East Respiratory Syndrome Coronavirus Replication in the Common Marmoset

Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals

Antibodies may curb pandemic before vaccines

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Structural basis of a shared antibody response to SARS-CoV-2

Potently neutralizing and protective human antibodies against SARS-CoV-2

A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes

REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters

Multi-Clonal Live SARS-CoV-2 In Vitro Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors

Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms

Animal and translational models of SARS-CoV-2 infection and COVID-19

The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice

A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures

Human angiotensin-converting enzyme 2 transgenic mice infected with SARS-CoV-2 develop severe and fatal respiratory disease

A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies

Pathogenesis of SARS-CoV-2 in Transgenic Mice Expressing Human Angiotensin-Converting Enzyme 2

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

COVID-19 preclinical models: human angiotensin-converting enzyme 2 transgenic mice

Evaluation of K18-hACE2 Mice as a Model of SARS-CoV-2 Infection

Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment

Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus

SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function

K18-hACE2 Mice for Studies of COVID-19 Treatments and Pathogenesis Including Anosmia. bioRxiv

A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection

Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Modulation of the effector functions of a human IgG1 through engineering of its hinge region

Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults

Structural insights into neonatal Fc receptor-based recycling mechanism

Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults

Acetylcholinesterase-Fc Fusion Protein (AChE-Fc): A Novel Potential Organophosphate Bioscavenger with Extended Plasma Half-Life

ACE2 mouse models: a toolbox for cardiovascular and pulmonary research

Extended therapeutic window for post-exposure treatment of ricin intoxication conferred by the use of high-affinity antibodies

Isolation and chimerization of a highly neutralizing antibody conferring passive protection against lethal Bacillus anthracis infection

Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies

A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge bioRxiv

We thank Prof. Dr. Christian Drosten at the Charité Universitätsmedizin, Institute of Virology, Berlin, Germany for providing the SARS-CoV-2 BavPat1/2020 strain. We wish to express our gratitude to our colleagues Dr. Hagit Achdout, Dr. Nir Paran, Dr. 

Patent application for the described antibody was filed by the Israel Institute for Biological Research. None of the authors declared any additional competing interests.